Objective:

To review evolving hemodynamic approaches aimed at optimizing septic shock management while limiting complications, particularly focusing on the integration of multimodal therapies.

Key Findings:

• Septic shock is driven by multiple pathophysiologic mechanisms leading to vasodilation, including inflammatory mediators and autonomic dysfunction.
• Current guidelines recommend at least 30 mL/kg of intravenous crystalloid for fluid resuscitation, with balanced crystalloids preferred.
• Norepinephrine is the first-line vasopressor, with vasopressin as a second-line agent, though evidence for adjunct therapies remains mixed.
• Early multimodal vasopressor therapy is gaining interest but lacks strong evidence for mortality benefit, highlighting the need for further research.
• Emerging biomarkers and AI tools may help personalize treatment, but many strategies are still supported by weak to moderate evidence.

Interpretation:

The review highlights the complexity of septic shock management and the critical need for individualized, evidence-based approaches to improve patient outcomes.

Limitations:

• Many strategies are supported by weak to moderate evidence, such as the mixed results from trials on fluid resuscitation and vasopressor use.
• Observational findings may be confounded and not indicative of causality, necessitating caution in interpretation.
• There is a pressing need for larger randomized trials to clarify optimal treatment approaches and validate emerging strategies.

Conclusion:

Future research should integrate physiologic monitoring, biomarker-guided therapy, and multimodal vasopressor strategies, focusing on specific patient populations to enhance septic shock management.